Expression of Netrin-1 and its Receptors in pNETs Abstract #604

Introduction: Netrin-1, a member of axon guidance molecules, and its dependence receptors (DCC, UNC5, neogenin) is involved in several cancer types (breast, neuroblastoma, colon etc) but its role in pNETs remains unknown.
Aim(s): Our aim was to determine the expression pattern of netrin-1 and its receptors in pNETs and to correlate with histoprognostic factors and evolution.
Materials and methods: Immunohistochemistry was performed on a Tissue Micro Array composed of 70 pNETs. Frozen samples of 25 pNETs (six insulinomas and 19 non-secreting tumors) were analyzed by RT-qPCR. We also assessed the expression of netrin-1 and its receptors in cell lines representative of pNETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Colette Roche

To read results and conclusion, please login ...

Further abstracts you may be interested in

#603 Role of Semaphorins and Their Signaling Pathway in the Progression of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: Semaphorin family, a part of axon guidance molecules, is involved in many types of epithelial cancers. However, little is known about its potential function in GEP-NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Colette Roche
#1707 Implication of Neuropilin-2 in the Progression of Small Intestinal Neuroendocrine Tumors: Towards a Promising Therapeutic Target?
Introduction: Small intestinal neuroendocrine tumors (siNETs) are rare tumors that raise several clinical and therapeutic challenges. Current treatments are not efficient, in part because of a poor understanding of their mechanisms of progression. We recently highlighted some axon guidance molecules (AGMs) that might be implicated in the progression of siNETs. Among them, we are currently focusing our efforts on the semaphorin 3F receptor neuropilin-2 (NRP2).
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D Julien Bollard
Keywords: siNETs, progression, NRP2
#1166 mTOR Pathway Inhibition Sensitizes Insulinoma Cells to Streptozotocin Induced Apoptosis
Introduction: Pancreatic neuroendocrine tumors (pNETs) are generally chemoresistants probably due to low proliferation rate and defects in apoptotic pathway. Targeted therapies are new encouraging options for pNETs however; clinical trials show limited objective response. Combination of chemotherapy and targeted therapy could be a new solution in therapeutic care. Streptozotocin (STZ) is the 1st line of therapy for unresectable pNETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Cécile Vercherat
#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: PhD Paula Jimenez-Fonseca
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist